UroGen Pharma (URGN) Liabilities and Shareholders Equity (2016 - 2026)

UroGen Pharma (URGN) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $253.7 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 2.45% year-over-year to $253.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $847.9 million (down 24.1% YoY) and the FY2025 annual result came in at $200.5 million, down 29.84% from the prior year.
• Liabilities and Shareholders Equity grew to $253.7 million in Q1 2026 per URGN's latest filing, from $200.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for URGN reached as high as $301.9 million in Q3 2024 and fell as low as $95.4 million in Q2 2023.
• A 5-year average of $195.4 million and a median of $193.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 195.56% — and 2025, when it slumped 38.71%.
• Year by year, Liabilities and Shareholders Equity stood at $135.6 million in 2022, then soared by 31.48% to $178.3 million in 2023, then surged by 60.23% to $285.7 million in 2024, then slipped by 29.84% to $200.5 million in 2025, then rose by 26.56% to $253.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $253.7 million, $200.5 million, and $185.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.